Mammary Cell News Volume 5.17 | May 2 2013

Monocytes Mediate Metastatic Breast Tumor Cell Adhesion to Endothelium under Flow
Since monocytes are highly represented in the tumor microenvironment, and also bind to endothelium during inflammation, investigators hypothesized that the monocytes assist in the arrest of MDA-MB-231 on the endothelium. [FASEB J] Abstract

Induction of Heme Oxygenase 1 and Inhibition of TPA-Induced Matrix Metalloproteinase-9 Expression by Andrographolide in MCF-7 Human Breast Cancer Cells
The authors investigated the effect of andrographolide on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced matrix metalloproteinase-9 expression and invasion in MCF-7 breast cancer cells and the possible mechanisms involved. [Carcinogenesis] Abstract

Parity Induces Differentiation and Reduces Wnt/Notch Signaling Ratio and Proliferation Potential of Basal Stem/Progenitor Cells Isolated from Mouse Mammary Epithelium
Since breast cancers are thought to arise from specific cell subpopulations of mammary epithelia, scientists studied the effect of parity on the transcriptome and the differentiation/proliferation potential of specific luminal and basal mammary cells in mice. [Breast Cancer Res] Abstract | Full Article | Press Release

Matrix Metalloproteinase-8 (Collagenase-2) Induces the Expression of Interleukins-6 and -8 in Breast Cancer Cells
The authors explored the effects of expression of either a wild-type (wt) or catalytically inactive mutant version of matrix metalloproteinase-8 (MMP-8) in human breast cancer cell lines. Analysis of serum-free conditioned media from three breast cancer cell lines expressing wt MMP-8 revealed elevated levels of interleukin-6 (IL-6) and IL-8. [J Biol Chem] Abstract | Full Article

A Novel Protoapigenone Analog RY10-4 Induces Breast Cancer MCF-7 Cell Death through Autophagy via the Akt/mTOR Pathway
Employing immunofluorescence assay for microtubule-associated protein light-chain 3 (LC3), monodansylcadaverine staining, western blotting analyses for LC3 and p62 as well as ultrastructural analysis by transmission electron microscopy, scientists showed that RY10-4 induced autophagy in MCF-7 cells but protoapigenone did not. [Toxicol Appl Pharmacol] Abstract

HDAC Inhibition Induces Increased Choline Uptake and Elevated Phosphocholine Levels in MCF7 Breast Cancer Cells
Researchers aimed to elucidate the underlying biochemical mechanism by which histone deacetylase (HDAC) inhibition leads to elevated phosphocholine (PC). They investigated the effect of SAHA on MCF-7 breast cancer cells using ¹³C MRS to monitor choline uptake and phosphorylation to PC. [PLoS One] Full Article

Oncolytic Bovine Herpesvirus Type 1 Infects and Kills Breast Tumor Cells and Breast Cancer-Initiating Cells Irrespective of Tumor Subtype
Bovine herpesvirus type 1 (BHV-1) is a species-specific herpesvirus that fails to induce cytopathic effects in normal human cells, but is capable of infecting and killing a variety of immortalized and transformed human cell types, including human breast tumor cell lines from luminal, basal A and basal B subtypes, representing a variety of receptor expression profiles. [Cancer Gene Ther] Abstract

A Physical Sciences Network Characterization of Non-Tumorigenic and Metastatic Cells
To investigate the transition from non-cancerous to metastatic from a physical sciences perspective, the Physical Sciences-Oncology Centers Network performed molecular and biophysical comparative studies of the non-tumorigenic MCF-10A and metastatic MDA-MB-231 breast epithelial cell lines, commonly used as models of cancer metastasis. [Sci Rep] Full Article | Press Release

CLINICAL RESEARCH

Selective Estrogen Receptor Modulators in Prevention of Breast Cancer: An Updated Meta-Analysis of Individual Participant Data
The authors assessed the effectiveness of selective estrogen receptor modulators on breast cancer incidence. They did a meta-analysis with individual participant data from nine prevention trials comparing four selective estrogen receptor modulators with placebo, or in one study with tamoxifen. [Lancet]
Abstract | Press Release

Combination Neratinib (HKI-272) and Paclitaxel Therapy in Patients with HER2-Positive Metastatic Breast Cancer
This was a phase I/II, open-label, two-part study. Part one was a dose-escalation study to determine the maximum tolerated dose (MTD) of neratinib plus paclitaxel in patients with solid tumors. Part two evaluated the safety, efficacy, and pharmacokinetics of the combination at the MTD in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. [Br J Cancer] Abstract

Breast Cancer: Improving Mouse Models
Researchers have developed a mouse model that resembles the claudin-low subtype of triple-negative breast cancer by expressing a weakly oncogenic MET receptor tyrosine kinase under the control of the mouse mammary tumor virus promoter concomitant with conditionally deleting Trp53 in the mammary gland. [Nat Rev Cancer] Abstract

Pharmacogenomics of Endocrine Therapy in Breast Cancer
On the basis of the results from genome-wide association studies, scientists have proceeded with functional genomic laboratory studies. This has led to new knowledge relating to endocrine biology that has provided a clear focus for further research to move toward truly personalized medicine for women with breast cancer. [J Hum Genet] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

GTx Initiating Phase II, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer
GTx, Inc. announced that it is initiating a proof of concept, Phase II, open-label clinical study to evaluate enobosarm, a selective androgen receptor modulator, for the potential treatment of metastatic breast cancer. [GTx, Inc.] Press Release

Repros’ Proellex® in Breast Cancer Phase II Study in Collaboration with Northwestern University
Repros Therapeutics Inc.® announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in the conduct of a physician sponsored IND investigating the potential for the use of Proellex® in the treatment of breast cancer in a window-of-opportunity design. [Repros Therapeutics Inc.] Press Release

STEMCELL Technologies Inc. Obtains License from iPS Academia Japan for Induced Pluripotent Stem Cell Technologies
STEMCELL Technologies Inc. has signed an agreement to license iPS Academia Japan’s induced pluripotent stem cell (iPS cell) technologies. This agreement will enable STEMCELL Technologies to develop media that are optimized for cellular reprogramming, further expanding its extensive portfolio of products designed to facilitate cutting-edge pluripotent stem cell research. [STEMCELL Technologies Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Postdoctoral Fellow – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai School of Medicine)

Research Associate (University of North Carolina at Charlotte, Department of Biology)

Postdoctoral Position – Hypoxia Signaling, Prolyl Hydroxylases and Cancer (UNC-Chapel Hill)

Postdoctoral Position – Breast Cancer (UT Southwestern Medical Center at Dallas)

Product Director – Breast Marketing (Genomic Health)

Postdoctoral Researcher – Cancer Genomics and Computational Biology/Bioinformatics (University of British Columbia/Provincial Health Services Authority)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.